Neurological outcome after emergency radiotherapy in MSCC of patients with non-small cell lung cancer--a prospective trial

Harald Rief, Rita C Heinhold, Lina C Petersen, Stefan Rieken, Thomas Bruckner, Arash Moghaddam-Alvandi, Jürgen Debus, Florian Sterzing, Harald Rief, Rita C Heinhold, Lina C Petersen, Stefan Rieken, Thomas Bruckner, Arash Moghaddam-Alvandi, Jürgen Debus, Florian Sterzing

Abstract

Background: The aim of this trial was to investigate neurological outcome after emergency RT in MSCC of NSCLC patients with acute neurological deficit.

Methods: This pilot trial was prospective, non-randomized, and monocentre, ten patients were treated from July 2012 until June 2013. After onset of neurological symptoms RT was started within 12 hours. The neurological outcome was assessed at baseline, and six weeks after RT using the ASIA Impairment Scale (AIS).

Results: The results showed an improved neurological outcome in one patient (10%), one patient (10%) had a decreased, and five patients (50%) a constant outcome after six weeks. Three patients (30%) died within the first six weeks following RT, additional 4 patients (40%) died within 4 month due to tumor progression.

Conclusion: In this group of NSCLC patients we were able to show that emergency RT in MSCC with acute neurological deficit had no considerable benefit in neurological outcome. Therefore, short-course regime or best supportive care due to poor survival should be considered for these patients with additional distant metastases. Patients with favorable prognosis may be candidates for long-course RT.

Trial registration: Clinical trial identifier NCT 02000518.

Trial registration: ClinicalTrials.gov NCT02000518.

Figures

Figure 1
Figure 1
Flow of participants through the trial.
Figure 2
Figure 2
Kaplan-Meier curve for survival (begin neurological symptom to death).

References

    1. Rades D, Fehlauer F, Schulte R. et al.Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;8:3388–3393. doi: 10.1200/JCO.2005.05.0542.
    1. Bach F, Larsen BH, Rohde K. et al.Metastatic spinal cord compression, occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir. 1990;8:37–43. doi: 10.1007/BF01402610.
    1. Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol. 2005;8(1):15–24.
    1. Yeung SCJ, Escalante CP. In: Holland-Frei Cancer Medicine. Seventh. Kufe DW, Bast RC, Hait W, Kufe DW, Bast RC, Hait W, editor. Hamilton, Ontario: BC Decker; 2006. Oncologic emergencies; p. 2328.
    1. Christian E, Adamietz IA, Willich N. et al.Radiotherapy in oncological emergencies – final results of a patterns of care study in Germany, Austria and Switzerland. Acta Oncol. 2008;8:81–89. doi: 10.1080/02841860701481554.
    1. El M, Tsobo M, Katoh S. et al.Validation of the American spinal injury association (ASIA) motor score and the national acute spinal cord injury study (NASCIS) motor score. Spine. 1996;8(5):614–619. doi: 10.1097/00007632-199603010-00015.
    1. Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guidline. J Clin Oncol. 1998;8(4):1613–1624.
    1. Rades D, Huttenlocher S, Evers NJ. et elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression? Strahlenther Onkol. 2012;8:424–430. doi: 10.1007/s00066-011-0058-z.
    1. Rades D, Fehlauer F, Stalpers LJ. et al.A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. Cancer. 2004;8(11):2687–2692. doi: 10.1002/cncr.20633.
    1. Maranzano E, Bellavita R, Rossi R. et al.Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol. 2005;8(15):3358–3365. doi: 10.1200/JCO.2005.08.193.
    1. Krassioukov A, Biering-Sørensen F, Donovan W. et al.International standards to document remaining autonomic function after spinal cord injury. J Spinal Cord Med. 2012;8(4):201–210. doi: 10.1179/1079026812Z.00000000053.
    1. Hoskin PJ, Grover A, Bhana R. Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiother Oncol. 2003;8:175–180. doi: 10.1016/S0167-8140(03)00191-9.
    1. Prewett S, Venkitaraman R. Metastatic spinal cord compression: review of the evidence for a radiotherapy dose fractionation schedule. Clin Oncol. 2010;8:222–230. doi: 10.1016/j.clon.2010.01.006.
    1. Rades D, Veninga T, Bajrovic A. et al.A validated scoring system to identify long-term survivors after radiotherapy for metastatic spinal cord compression. Strahlenther Onkol. 2013;8:462–466. doi: 10.1007/s00066-013-0342-1.
    1. Rades D, Douglas S, Veninga T. et al.A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer. 2012;8:302. doi: 10.1186/1471-2407-12-302.
    1. Loblaw DA, Mitera G. The optimal dose fractionation schema for malignant extradural spinal cord compression. J Support Oncol. 2011;8(4):121–124. doi: 10.1016/j.suponc.2011.04.004.
    1. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. Eur J Cancer. 1994;8:22–27. doi: 10.1016/S0959-8049(05)80011-5.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi